The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase
- 1 January 2006
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 46 (1), 88-102
- https://doi.org/10.1177/0091270005282634
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenaseLife Sciences, 2005
- Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.Nucleosides, Nucleotides and Nucleic Acids, 2004
- An Extremely Potent Inhibitor of Xanthine OxidoreductaseJournal of Biological Chemistry, 2003
- The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994American Journal of Kidney Diseases, 2002
- Gout and Risk for Subsequent Coronary Heart DiseaseArchives of Internal Medicine, 1997
- Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzeesEuropean Journal of Pharmacology, 1993
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodentsEuropean Journal of Pharmacology, 1993
- Superiority of the Child-Pugh Classification to Quantitative Liver Function Tests for Assessing Prognosis of Liver CirrhosisScandinavian Journal of Gastroenterology, 1989
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973